RESEARCH TRIANGLE PARK, N.C.
, May 12
/PRNewswire/ -- The International Collaborative Cancer Group, in collaboration with the Institute of Cancer Research Clinical Trials and Statistics Unit, is running the Intergroup Exemestane Study (IES). IES is a randomized, double blind multinational trial of post menopausal women with early breast cancer and a median follow-up period of 91 months. Max Neeman
will be responsible for the compilation of the data from multiple centers.
This landmark trial has the longest follow-up of endocrine treatment in the adjuvant switch setting with approximately 2300 patients from across the globe. The study evaluates the clinical benefits of switching over to Aromasin after two to three years of Tamoxifen in comparison with patients put on only Tamoxifen for a full, five year period.
Max Neeman provides Data Management/EDC service for large Phase IV multicentric trials to companies across the globe, in 60 countries to date. Max Neeman also conducts post-marketing observational studies for multiple indications of hypertension, contact dermatitis, acute coronary syndrome, cessation of smoking, renal carcinoma, breast carcinoma, age related macular degeneration and fungal infections.
About Max Neeman International
Max Neeman International is one of the leading and largest CROs in India. Our specialty is that we offer services for the successful conduct of Phase I-IV clinical and device trials for small and mid-sized international and national Pharmaceutical, Biotechnology, Medical Device and Nutraceutical companies in compliance with ICH GCP standards. Operational since 2001, Max Neeman is an ISO 9001:2008 certified CRO for Monitoring, Site Management and Data Management Services. The company is presently active in 22 cities with 5 regional offices. Contact Donald Swankie, Vice President of Business Development, for more information via email to email@example.com or call +1.919.424.3345. For more information please visit www.neeman-medical.com.
SOURCE Max Neeman International